These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38933256)

  • 1. THE EFFECT OF PARICALCITOL AND CALCITRIOL WITH OR WITHOUT CALCIMIMETICS ON PULSE WAVE VELOCITY AND SERUM LEVELS FOR PARATHYROID HORMONE, CALCIUM AND PHOSPHORUS IN MAINTENANCE HEMODIALYSIS PATIENTS.
    Bal AZ; Bal U; Akdogan M; Sezer S
    Acta Endocrinol (Buchar); 2023; 19(4):480-486. PubMed ID: 38933256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients.
    Kumar J; Tran NT; Schomberg J; Streja E; Kalantar-Zadeh K; Pahl M
    J Ren Nutr; 2016 Jul; 26(4):265-9. PubMed ID: 27038806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparison of paricalcitol and calcitriol effects on pulse wave velocity, osteocalcin, and fetuin-A in chronic hemodialysis patients.
    Karakose S; Bal Z; Sezer S
    Semin Dial; 2024; 37(2):131-137. PubMed ID: 37392044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential influence of vitamin D analogs on left ventricular mass index in maintenance hemodialysis patients.
    Sezer S; Tutal E; Bal Z; Uyar ME; Bal U; Cakir U; Acar NO; Haberal M
    Int J Artif Organs; 2014 Feb; 37(2):118-25. PubMed ID: 24619898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.
    Teng M; Wolf M; Lowrie E; Ofsthun N; Lazarus JM; Thadhani R
    N Engl J Med; 2003 Jul; 349(5):446-56. PubMed ID: 12890843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study.
    Coyne DW; Andress DL; Amdahl MJ; Ritz E; de Zeeuw D
    Nephrol Dial Transplant; 2013 Sep; 28(9):2260-8. PubMed ID: 23787544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study.
    Mittman N; Desiraju B; Meyer KB; Chattopadhyay J; Avram MM
    Kidney Int Suppl; 2010 Aug; (117):S33-6. PubMed ID: 20671742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
    Llach F; Yudd M
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis.
    Thadhani RI; Rosen S; Ofsthun NJ; Usvyat LA; Dalrymple LS; Maddux FW; Hymes JL
    Clin J Am Soc Nephrol; 2020 Mar; 15(3):384-391. PubMed ID: 32111702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols.
    Shalhoub V; Shatzen E; Henley C; Boedigheimer M; McNinch J; Manoukian R; Damore M; Fitzpatrick D; Haas K; Twomey B; Kiaei P; Ward S; Lacey DL; Martin D
    Calcif Tissue Int; 2006 Dec; 79(6):431-42. PubMed ID: 17171500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
    Sprague SM; Llach F; Amdahl M; Taccetta C; Batlle D
    Kidney Int; 2003 Apr; 63(4):1483-90. PubMed ID: 12631365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
    Noonan W; Koch K; Nakane M; Ma J; Dixon D; Bolin A; Reinhart G
    Nephrol Dial Transplant; 2008 Dec; 23(12):3824-30. PubMed ID: 18644798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of vitamin D analogs on vascular calcification.
    Cardús A; Panizo S; Parisi E; Fernandez E; Valdivielso JM
    J Bone Miner Res; 2007 Jun; 22(6):860-6. PubMed ID: 17352647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.
    Abdul Gafor AH; Saidin R; Loo CY; Mohd R; Zainudin S; Shah SA; Norella KC
    Nephrology (Carlton); 2009 Aug; 14(5):488-92. PubMed ID: 19298641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.
    Jamaluddin EJ; Gafor AH; Yean LC; Cader R; Mohd R; Kong NC; Shah SA
    Clin Exp Nephrol; 2014 Jun; 18(3):507-14. PubMed ID: 23903802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
    Goldenberg MM
    Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients.
    Dusilová-Sulková S; Šafránek R; Vávrová J; Horáček J; Pavlíková L; Palička V
    Int Urol Nephrol; 2015 Jan; 47(1):169-76. PubMed ID: 25262147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease.
    Monier-Faugere MC; Mawad H; Malluche HH
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1255-60. PubMed ID: 17942766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.